ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 39.7% during trading on Tuesday . The stock traded as high as GBX 7.14 ($0.09) and last traded at GBX 5.50 ($0.07). 53,455,387 shares traded hands during trading, an increase of 148% from the average session volume of 21,559,516 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The firm’s 50-day simple moving average is GBX 1.98 and its 200 day simple moving average is GBX 1.80. The firm has a market capitalization of £19.99 million, a price-to-earnings ratio of -480.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- How to Invest in the FAANG Stocks
- Coinbase Gains Momentum on App Store—What It Means for the Stock
- Learn Technical Analysis Skills to Master the Stock Market
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Steel Stocks Soaring After Tariff Announcements
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
